Avid prepares to present findings of Alzheimer's study

06/23/2010 | New York Times (tiered subscription model), The

Avid Radiopharmaceuticals, a company that developed fluoride 18-based dyes for use in PET scans of amyloid plaques, said it has received the results of a study using its dye to determine whether Alzheimer's disease diagnosed through a PET scan correlates with that determined through a brain autopsy. The results, to be presented at the Alzheimer's Association meeting next month, will "have a big impact on Alzheimer's disease," said Dr. Daniel Skovronsky, founder of the company.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA